{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:07:34Z","timestamp":1789103254885,"version":"build-2803163510"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>It is challenging to manage locally advanced non-small cell lung cancer (NSCLC) in patients older than 85 years, as there is neither a guideline nor evidence for guidance. Most clinical trials excluded this population for enrollment. Here we report a case of a 90-year-old former smoker with squamous cell carcinoma of the left upper lung, FDG-PET\/CT staged IIIC cT4N3M0 (the 8th Edition of the UICC\/AJCC Staging System). The patient, representing the population of older patients, was remarkable for extensive vertebrae body invasion with the primary tumor abutting the true spinal cord. Our multidisciplinary team consultation rendered him with unresectable tumors in a medically inoperable condition. The patient was treated with concurrent chemoradiation therapy to a tumor dose of 60 Gy in 30 fractions, using an imaging-guided adaptive technique to keep the cord in a safe dose limit, similar to that of RTOG1106. The patient had quick and lasting pain relief and tumor shrinkage during the course of therapy, which allowed adaptive cord-sparing therapy. The patient completed the definitive course of chemoradiation with Grade I\/II radiation esophagitis and Grade IV neutropenic fever. He did not have subsequent immunotherapy maintenance. He is now almost 6 years out from the lung cancer diagnosis, with excellent performance status without any evidence of disease progression. His tumor continuously shrunk 3 years after the completion of radiotherapy; the destroyed bone recovered to a normal appearance. He has no evidence of disease progression nor any notable side effects. The success of this case implicates that the curative potential of concurrent chemotherapy with precision personalized adaptive therapy alone without adjuvant immunotherapy in the extremely old population. Future prospective studies are needed.<\/jats:p>","DOI":"10.3389\/fonc.2026.1896102","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:32:08Z","timestamp":1789101128000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Can this 90-year-old patient with cT4N3M0 NSCLC have concurrent chemoradiation for cure? Learning from a representive case"],"prefix":"10.3389","volume":"16","author":[{"given":"Cuimeng","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Beijing Chest Hospital, Capital Medical University\/Beijing Tuberculosis and Thoracic Tumor Research Institute","place":["Beijing, China"]},{"name":"Department of Thoracic Oncology, Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenji","family":"Pu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital","place":["Shenzhen, China"]},{"name":"Department of Radiation Oncology, Shenzhen Nanshan People's Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing Cheung","family":"Mathew Yik","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Tuen Mun Hospital","place":["Hong Kong, Hong Kong SAR, China"]},{"name":"Department of Radiotherapy, Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital","place":["Shenzhen, China"]},{"name":"Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong","place":["Hong Kong, Hong Kong SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biaoda","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Hong Kong-Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ming (Spring)","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital","place":["Shenzhen, China"]},{"name":"Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong","place":["Hong Kong, Hong Kong SAR, China"]},{"name":"Departments of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital and Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong","place":["Hong Kong, Hong Kong SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00022","article-title":"Primary results of NRG-RTOG1106\/ECOG-ACRIN 6697: A randomized phase II trial of individualized adaptive (chemo)radiotherapy using midtreatment (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in stage III non-small cell lung cancer","volume":"42","author":"Kong","year":"2024","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(12)70139-0","article-title":"Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)","volume":"13","author":"Atagi","year":"2012","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01155-w","article-title":"Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer","volume":"40","author":"Omori","year":"2022","journal-title":"Invest New Drug"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00627","article-title":"Selective personalized radioimmunotherapy for locally advanced non-small-cell lung cancer trial (SPRINT)","volume":"42","author":"Ohri","year":"2024","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.3309","article-title":"Durvalumab plus concurrent radiotherapy for treatment of locally advanced non-small cell lung cancer: The DOLPHIN phase 2 nonrandomized controlled trial","volume":"9","author":"Tachihara","year":"2023","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29423","article-title":"Four-phase, definitive chemoradiation for a real-world (poor risk and\/or elderly) patient population with locally advanced non-small cell lung cancer","volume":"14","author":"Zhou","year":"2022","journal-title":"Cureus J Med Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: The phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.3390\/cancers13184534","article-title":"Elderly patients with locally advanced and unresectable non-small-cell lung cancer may benefit from sequential chemoradiotherapy","volume":"13","author":"Zaborowska-Szmit","year":"2021","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz039","article-title":"Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter phase I\/II study","volume":"49","author":"Niho","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0982","article-title":"Effect of midtreatment PET\/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: A phase 2 clinical trial","volume":"3","author":"Kong","year":"2017","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.011","article-title":"Impact of age on outcomes with immunotherapy in patients with non-small cell lung cancer","volume":"14","author":"Lichtenstein","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.08.003","article-title":"Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter","volume":"60","author":"Ferrara","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.06.018","article-title":"Phase 2 trial assessing toxicity of personalized response-based radiation treatment in patients with locally advanced non-small cell lung cancer","volume":"120","author":"Edwards","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2023.2188935","article-title":"Function of stem cells in radiation-induced damage","volume":"99","author":"Liu","year":"2023","journal-title":"Int J Radiat Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.08.008","article-title":"Simultaneous targeting of TGF-beta\/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion","volume":"39","author":"Lan","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1896102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:32:32Z","timestamp":1789101152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1896102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1896102"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1896102","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1896102"}}